Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2017
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
355
-1.06%
|
$28,045
$79.69 P/Share
|
|
Feb 16
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
61,196
-68.03%
|
$4,895,680
$80.0 P/Share
|
|
Feb 16
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
61,196
+40.49%
|
$2,203,056
$36.23 P/Share
|
|
Feb 01
2017
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
76,494
-24.0%
|
$5,966,532
$78.32 P/Share
|
|
Feb 01
2017
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,494
+19.36%
|
$2,753,784
$36.23 P/Share
|
|
Nov 02
2016
|
Richard J Swift Director |
BUY
Grant, award, or other acquisition
|
Direct |
737
+11.35%
|
$61,171
$83.95 P/Share
|
|
Nov 02
2016
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,317
+20.07%
|
$109,311
$83.95 P/Share
|
|
Nov 02
2016
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+15.93%
|
$103,750
$83.95 P/Share
|
|
Nov 02
2016
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,394
+4.46%
|
$281,702
$83.95 P/Share
|
|
Nov 02
2016
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+50.0%
|
$103,750
$83.95 P/Share
|
|
Nov 02
2016
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+50.0%
|
$103,750
$83.95 P/Share
|
|
Nov 02
2016
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+5.45%
|
$103,750
$83.95 P/Share
|
|
May 19
2016
|
Richard J Swift Director |
BUY
Grant, award, or other acquisition
|
Direct |
612
+10.86%
|
$61,200
$100.95 P/Share
|
|
May 19
2016
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,095
+21.8%
|
$109,500
$100.95 P/Share
|
|
May 19
2016
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+16.29%
|
$104,000
$100.95 P/Share
|
|
May 19
2016
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,823
+3.91%
|
$282,300
$100.95 P/Share
|
|
May 19
2016
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+50.0%
|
$104,000
$100.95 P/Share
|
|
May 19
2016
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+50.0%
|
$104,000
$100.95 P/Share
|
|
May 19
2016
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+4.84%
|
$104,000
$100.95 P/Share
|
|
May 05
2016
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
38,247
-13.64%
|
$4,015,935
$105.0 P/Share
|
|
May 05
2016
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
38,247
+12.0%
|
$1,376,892
$36.23 P/Share
|
|
May 05
2016
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,517
-9.75%
|
$789,285
$105.0 P/Share
|
|
May 05
2016
|
Stephen J Gold EVP & CIO |
SELL
Open market or private sale
|
Direct |
9,798
-31.25%
|
$1,028,790
$105.0 P/Share
|
|
May 05
2016
|
Stephen J Gold EVP & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,798
+23.81%
|
$460,506
$47.29 P/Share
|
|
Apr 02
2016
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,192
-9.0%
|
$331,968
$104.82 P/Share
|
|
Apr 01
2016
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,160
+15.41%
|
$3,968,640
$104.82 P/Share
|
|
Apr 01
2016
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,583
-6.77%
|
$1,828,632
$104.82 P/Share
|
|
Apr 01
2016
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,465
+26.11%
|
$2,232,360
$104.82 P/Share
|
|
Apr 01
2016
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
9,540
+20.7%
|
$992,160
$104.82 P/Share
|
|
Apr 01
2016
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct |
4,411
-8.77%
|
$458,744
$104.82 P/Share
|
|
Apr 01
2016
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
9,540
+5.66%
|
$992,160
$104.82 P/Share
|
|
Apr 01
2016
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,902
-8.26%
|
$1,341,808
$104.82 P/Share
|
|
Apr 01
2016
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,540
+22.59%
|
$992,160
$104.82 P/Share
|
|
Apr 01
2016
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,972
-10.23%
|
$309,088
$104.82 P/Share
|
|
Apr 01
2016
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,155
+16.36%
|
$744,120
$104.82 P/Share
|
|
Apr 01
2016
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,924
-8.24%
|
$720,096
$104.82 P/Share
|
|
Apr 01
2016
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
6,439
+13.61%
|
$669,656
$104.82 P/Share
|
|
Apr 01
2016
|
Stephen J Gold EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,546
-6.69%
|
$160,784
$104.82 P/Share
|
|
Apr 01
2016
|
Stephen J Gold EVP & CIO |
SELL
Open market or private sale
|
Direct |
21,922
-52.14%
|
$2,301,810
$105.0 P/Share
|
|
Apr 01
2016
|
Stephen J Gold EVP & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,922
+34.27%
|
$1,030,334
$47.29 P/Share
|
|
Apr 01
2016
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,862
+14.05%
|
$297,648
$104.82 P/Share
|
|
Apr 01
2016
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,339
+15.66%
|
$347,256
$104.82 P/Share
|
|
Apr 01
2016
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,155
-1.76%
|
$120,120
$104.82 P/Share
|
|
Apr 01
2016
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,247
+18.83%
|
$545,688
$104.82 P/Share
|
|
Apr 01
2016
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,625
-11.69%
|
$481,000
$104.82 P/Share
|
|
Apr 01
2016
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
3,100
+15.19%
|
$322,400
$104.82 P/Share
|
|
Apr 01
2016
|
Andrew Sussman EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,319
-9.56%
|
$137,176
$104.82 P/Share
|
|
Apr 01
2016
|
Andrew Sussman EVP, Clinical Services |
SELL
Open market or private sale
|
Direct |
2,844
-20.48%
|
$298,620
$105.0 P/Share
|
|
Apr 01
2016
|
Robert O. Kraft EVP and President - Omnicare |
BUY
Grant, award, or other acquisition
|
Direct |
3,100
+3.38%
|
$322,400
$104.82 P/Share
|
|
Mar 09
2016
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
38,247
-14.64%
|
$3,824,700
$100.0 P/Share
|